Our study therefore suggests miR-128 and Wnt1/β-catenin as potential cardiac therapeutic targets and provides a promising therapeutic insight into the treatment of cardiac hypertrophy and heart failure. The gene discussed is WNT1; the disease is cardiac hypertrophy.